LLY. FDA approves updated prescribing information for Tradjenta® (linagliptin) tablets for add-on therapy to insulin in adults with type 2 diabetes Updated label also includes data on adult patients with type 2 diabetes who have severe chronic renal impairment, providing further evidence TRADJENTA is an efficacious DPP-4 inhibitor with a demonstrated safety profile http://finance.yahoo.com/news/fda-approves-updated-prescribing-information-185200943.html